预约演示
更新于：2025-09-20
Ipratropium Bromide
异丙托溴铵
更新于：2025-09-20
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H32BrNO4 |
InChIKeyKEWHKYJURDBRMN-ZEODDXGYSA-M |
CAS号66985-17-9 |
关联
114
项与 异丙托溴铵 相关的临床试验CTR20252731
单中心、随机、开放、两序列、两周期交叉设计评估中国健康研究参与者非炭阻、空腹状态下经口吸入异丙托溴铵吸入气雾剂的生物等效性试验
CTR20250540
异丙托溴铵吸入气雾剂人体生物等效性研究
CTIS2024-514065-19-00
PHASE III, DOUBLE-BLIND, RANDOMIZED, CONTROLLED, NON-INFERIORITY, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY OF SALBUTAMOL MONOTHERAPY COMPARED TO SALBUTAMOL PLUS IPRATROPIUM BROMIDE IN THE MANAGEMENT OF MODERATE ACUTE ASTHMATIC EXARCEBATIONS IN CHILDREN IN THE EMERGENCY DEPARTMENT
100 项与 异丙托溴铵 相关的临床结果
登录后查看更多信息
100 项与 异丙托溴铵 相关的转化医学
登录后查看更多信息
100 项与 异丙托溴铵 相关的专利（医药）
登录后查看更多信息
2,216
项与 异丙托溴铵 相关的文献（医药）2025-09-12Scientific Reports
Amitriptyline inhibits bronchoconstriction independent of direct receptor binding and reduces number of caveolae.
Article
作者: Martin, Christian ; Katona, Istvan ; Klein, Virag ; Hempel, Paulina ; Michely, Anna ; Tenbrock, Klaus ; Verjans, Eva
Bronchial asthma is a chronic inflammatory disease with rising prevalence worldwide. Apart from the immunological role of the tricyclic antidepressant amitriptyline in bronchial asthma, there is emerging evidence that inhaled amitriptyline directly reduces acute bronchoconstriction. However, the mechanism by which amitriptyline influences bronchial tone remains poorly understood. To influence bronchoconstriction, rat precision-cut lung slices treated with varying concentrations of amitriptyline (0-5 µM) and incubated with inhibitors targeting different signaling pathways. Amitriptyline reduces acetylcholine- and serotonin-induced bronchoconstriction. Neither the muscarinic antagonist ipratropium nor the phospholipase C inhibitor U73122, nor the protein kinase C inhibitor chelerythrine diminished the effect of amitriptyline. Inhibition of calcium sensitizing and induction failed to alter amitriptyline's effect on bronchoconstriction. Caveolae-as part of the plasma membrane-display a microenvironment, where regulation of signal transduction takes place. Similar to methyl ß cyclodextrin (MBCD), a common substance to destroy caveolae, amitriptyline dramatically reduced the number of caveolae in lung tissue. However, unlike MBCD, this effect could not be explained by cholesterol depletion alone, as cholesterol repletion did not reverse amitriptyline's effect. Furthermore, neither simvastatin (a lipid lowering agent) nor cytochalasin D (an inhibitor of actin polymerization), influenced the inhibitory effect of amitriptyline on bronchoconstriction. In conclusion, amitriptyline inhibits bronchoconstriction independently of direct receptor binding or interaction. It also reduces the total number of caveolae without effects on cholesterol lowering pathways or actin depolymerization. A more general mechanism seems likely, as inhibition of single signal transduction pathways failed. Further studies are required to elucidate the underlying mechanisms.
2025-08-01Cureus Journal of Medical Science
Stepwise Management of Status Asthmaticus Refractory to Initial Therapy: A Case Report.
Article
作者: Singh, Sumi ; Chowdhury, Shafayath ; Shen, Kevin ; Weissman, Brandon
Asthma is one of the most prevalent chronic respiratory illnesses, significantly impacting patients through shortness of breath and even death. Acute exacerbations are usually controlled with a short-acting beta agonist, such as an albuterol inhaler, as well as long-acting agents to prevent the occurrence of exacerbations and status asthmaticus. Status asthmaticus is an emergent episode of asthma that is refractory to standard treatment. This disease presents as tachycardia, tachypnea, and dyspnea. The forced expiratory volume measures the severity of asthma in one second and the serial peak expiratory flow rate. Proper treatment is vital for patient survival. This case report reviews the proper treatment of a patient in her mid-30s presenting to the emergency department due to an asthmatic attack refractory to albuterol. The patient went through a five-stage treatment plan. First, the patient was treated with inhaled beta-2 agonist (albuterol) and corticosteroids (prednisone, dexamethasone, and methylprednisolone). The patient did not improve with these treatments and was given the anticholinergic agent ipratropium bromide in an attempt to increase bronchodilation. Nebulized racemic epinephrine was then added to the patient to optimize maximum bronchodilation and vasoconstriction in an attempt to reduce airway edema and inflammation. To reduce ventilator peak airway pressures through sedation and paralytics, rocuronium and cisatracurium (Nimbex) were administered. Ketamine was added as a sedative and bronchodilator. Propofol and midazolam (Versed) were used to sedate the patient for mechanical ventilation. After the acute episode, maintenance therapy included inhaled corticosteroids (budesonide), a long-acting beta-2 agonist (arformoterol), a long-acting muscarinic antagonist (revefenacin), and montelukast (a leukotriene receptor antagonist). This case illustrates the importance of status asthmaticus treatment as a vital, stepwise process that focuses on bronchodilation, maintaining the airway, mechanical ventilation, sedation, and reducing inflammation and paralysis.
2025-07-01RESPIRATORY MEDICINE
Inhalers or nebulisation of salbutamol in childhood asthma exacerbations in emergency departments
Article
作者: Lopes, Anne-Aurélie ; Lemaçon, Clara
PURPOSE:
Asthma exacerbations often lead to paediatric emergency department (PED) visits, but evidence for paediatric management remains limited, and recommendations under discussion. This study compared salbutamol delivered via nebulisation and pressurised metered dose inhalers (pMDI) with a holding chamber in children with mild to severe asthma exacerbations.
METHODS:
A two-centre study was conducted during eight months, comparing hospitalisation rates, clinical improvement, side effects, and PED visit length in the overall population and in children under and over 6 years old.
RESULTS:
A total of 384 patients were included, primarily with mild and moderate exacerbations of similar severity between groups. The discharge rate was comparable between groups in the overall population (82.7 % without any nebulisation in the pMDI group versus 81.6 %, p = 0.93), but higher for children under 6 years old treated with pMDI (98.1 % versus 76.9 %, p < 0.001). The pMDI group exhibited significantly lower hospitalisation rates (p < 0.001) and shorter PED visits (1.7 [1.2-2.6] hours versus 4.0 [2.6-5.3] hours, p < 0.001) while receiving lower salbutamol doses (0.10 [0.05-0.16] mg/kg versus 0.81 [0.55-1.18] mg/kg, p < 0.001) with less ipratropium and oral corticosteroids (p < 0.001 and p < 0.001). The pMDI group demonstrated fewer side effects, particularly oxygen dependence, especially in children under 6 (p < 0.001).
CONCLUSION:
The study suggests that salbutamol via pMDI with a holding chamber is as effective as nebulisation for treating mild to moderate childhood asthma exacerbations. This approach results in fewer hospitalisations, reduced side effects, and shorter PED visits. Educating patients on pMDI use and efficacy could further decrease emergency visits for asthma exacerbation.
100 项与 异丙托溴铵 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2000-10-27 | |
| 普通感冒 | 美国 | 1995-10-20 | |
| 鼻炎 | 美国 | 1995-10-20 | |
| 支气管痉挛 | 美国 | 1993-09-29 | |
| 慢性阻塞性肺疾病 | 美国 | 1993-09-29 | |
| 哮喘 | 日本 | 1980-10-25 | |
| 慢性支气管炎 | 日本 | 1980-10-25 | |
| 肺气肿 | 日本 | 1980-10-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 呼吸困难 | 临床阶段不明 | 加拿大 | 2008-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 141 | (Levalbuterol) | 襯廠鑰鏇夢窪選選網鑰 = 製鏇膚製網網簾範獵膚 選襯繭鹹觸繭餘衊夢夢 (餘選觸襯範窪網窪鹽網, 鬱餘醖淵餘鏇壓範繭積 ~ 鹽衊遞襯齋網鹽鬱襯鹹) 更多 | - | 2022-05-16 | ||
(Levalbuterol Plus Ipratropium) | 襯廠鑰鏇夢窪選選網鑰 = 製夢廠顧顧襯夢鹹簾憲 選襯繭鹹觸繭餘衊夢夢 (餘選觸襯範窪網窪鹽網, 網遞積鬱願網齋淵艱願 ~ 選顧繭夢製繭憲顧願製) 更多 | ||||||
临床4期 | 40 | 窪鬱觸顧鹹衊齋製獵鹽(鏇範醖獵選壓醖壓窪網) = 窪廠鬱網齋鏇網顧鏇糧 淵製範夢醖廠鏇構獵齋 (範鏇淵積繭獵窪壓齋膚, 25.2) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 窪鬱觸顧鹹衊齋製獵鹽(鏇範醖獵選壓醖壓窪網) = 築壓壓淵獵遞夢觸醖築 淵製範夢醖廠鏇構獵齋 (範鏇淵積繭獵窪壓齋膚, 19.8) 更多 | ||||||
临床4期 | 20 | Placebo (Placebo) | 構餘築醖餘夢遞鏇憲遞(廠顧蓋鏇願鬱衊廠構蓋) = 壓簾淵醖膚鹽觸製繭遞 觸鹹襯網積鏇淵鏇觸獵 (構膚鑰窪襯鑰鹹壓選壓, 鬱繭簾顧窪夢憲鹽夢壓 ~ 蓋遞膚淵製構齋構壓構) 更多 | - | 2020-06-05 | ||
(Ipratropium Bromide) | 構餘築醖餘夢遞鏇憲遞(廠顧蓋鏇願鬱衊廠構蓋) = 鹽製製構選願構鹽襯齋 觸鹹襯網積鏇淵鏇觸獵 (構膚鑰窪襯鑰鹹壓選壓, 製鏇廠遞淵網膚顧廠蓋 ~ 艱範蓋顧願顧淵鑰衊醖) 更多 | ||||||
临床4期 | 20 | (Ipratropium) | 選鬱繭憲鑰廠構壓糧鏇(顧夢鹽網淵構願遞壓餘) = 積齋鏇鑰繭鏇憲齋願艱 襯範膚鹽鏇鏇齋餘蓋獵 (積築衊齋積蓋齋簾簾糧, 鬱夢淵窪蓋蓋襯糧夢窪 ~ 廠醖鹽獵憲鬱齋構鑰網) 更多 | - | 2016-10-12 | ||
(Theophylline) | 選鬱繭憲鑰廠構壓糧鏇(顧夢鹽網淵構願遞壓餘) = 窪願蓋餘膚簾醖襯觸願 襯範膚鹽鏇鏇齋餘蓋獵 (積築衊齋積蓋齋簾簾糧, 餘築齋獵艱糧選遞觸齋 ~ 積齋糧築簾鹹蓋餘繭憲) 更多 | ||||||
临床4期 | 192 | placebo | 蓋鑰築鑰構糧衊鏇鏇壓(願膚齋獵壓構艱製艱壓) = 艱壓鹹鏇網獵鹽糧壓網 襯淵鏇遞齋鏇範願網蓋 (範醖構簾積齋廠餘醖壓, 29.35) 更多 | - | 2016-09-12 | ||
临床3期 | 15 | (Albuterol-sulphate) | 築壓願餘網構繭淵蓋淵(夢鹽襯築鑰積鹹築餘蓋) = 鑰遞鹽醖壓鏇積蓋蓋醖 積壓製範膚襯衊顧窪夢 (糧簾膚範鏇構衊觸繭鹽, 13.6) 更多 | - | 2016-06-02 | ||
(Ipratropium-bromide (Atrovent ®)) | 築壓願餘網構繭淵蓋淵(夢鹽襯築鑰積鹹築餘蓋) = 鏇糧糧醖簾選繭願艱鬱 積壓製範膚襯衊顧窪夢 (糧簾膚範鏇構衊觸繭鹽, 10.9) 更多 | ||||||
N/A | - | Salbutamol, Prednisolone, and Ipratropium Bromide | 廠鑰積廠網鹽憲製遞願(襯網醖壓積壓鏇艱艱衊) = 壓繭簾鏇鬱衊餘廠範蓋 醖衊鏇襯膚艱憲鏇鏇積 (糧壓觸顧積範獵襯襯糧 ) 更多 | - | 2015-02-01 | ||
Salbutamol and Prednisolone | 廠鑰積廠網鹽憲製遞願(襯網醖壓積壓鏇艱艱衊) = 憲醖鑰積鑰艱獵觸齋糧 醖衊鏇襯膚艱憲鏇鏇積 (糧壓觸顧積範獵襯襯糧 ) 更多 | ||||||
临床4期 | 581 | (Symbicort Turbuhaler + Ipratropium + Theophylline SR) | 積餘顧膚艱艱糧積憲醖(壓繭淵鏇簾構糧夢獵鬱) = 遞鏇鏇襯構醖鏇餘醖壓 選築鹹壓築醖獵鑰餘鬱 (醖鹹築顧構遞廠廠顧顧, 願網壓積築膚鑰齋積鹹 ~ 鑰醖構構築鏇繭窪鹽艱) 更多 | - | 2014-08-26 | ||
(Ipratropium + Theophylline SR) | 積餘顧膚艱艱糧積憲醖(壓繭淵鏇簾構糧夢獵鬱) = 餘膚衊積鹹廠壓遞鏇醖 選築鹹壓築醖獵鑰餘鬱 (醖鹹築顧構遞廠廠顧顧, 簾鏇醖窪繭醖糧糧築鑰 ~ 鑰鑰壓繭顧衊衊醖衊範) 更多 | ||||||
临床4期 | 56 | (Albuterol/Salbutamol Followed by Ipratropium) | 遞鑰鹽鹹窪範繭鏇艱築(製衊築糧築艱艱簾鑰獵) = 築膚壓鏇醖獵膚獵簾遞 壓廠鬱願鹽壓廠願鹹築 (鹹蓋製簾糧獵衊選鹹膚, 0.0394) 更多 | - | 2013-12-25 | ||
(Ipratropium Followed by Albuterol/Salbutamol) | 遞鑰鹽鹹窪範繭鏇艱築(製衊築糧築艱艱簾鑰獵) = 醖選願鹹繭顧願憲衊觸 壓廠鬱願鹽壓廠願鹹築 (鹹蓋製簾糧獵衊選鹹膚, 0.0372) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用